FoRx Therapeutics
FoRx Therapeutics is a biotechnology company developing a new generation of cancer drugs focusing on novel DNA Replication Stress pathways.
FoRx Therapeutics has raised €53M across 2 funding rounds from 4 investors, most recently a Series A round in Dec 2025. Based in Basel, Switzerland; founded 2019; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€53M
€52,691,257
Funding rounds
2
Investors
4
distinct backers
Active since
2020-04
latest 2025-12
Funding by year
EUR raised per yearFoRx Therapeutics — funding by year — interactive chart.
Data table
| FoRx Therapeutics — funding by year | |
|---|---|
| 2020 | €10M |
| 2025 | €43M |
Signals
High confidenceRaise-next likelihood54
base rate 44% for Series A
- ▲ In typical raise window
- ▲ Up-round momentum
- ▼ Low backer re-investment
Exit likelihood19
base rate 11% (2+ rounds)
- ▲ €30M+ raised
- ▲ 7y since founding (typical exit age)
- ▲ Recently backed by strong-exit-track investors
Timing: in window vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-12-19 | Series A | €43M | EQT Life Sciences,M Ventures,Novartis Venture Fund,Pfizer Ventures | View deal → |
| 2020-04-22 | Seed | €10M | M Ventures | View deal → |
Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
- Neko Health€924MSweden · Healthtech
- Climeworks€919MSwitzerland · Cleantech
Global coverage: FundingData